Core Viewpoint - Lifeward Ltd. and MYOLYN, Inc. are expanding their exclusive contract to enhance patient access to the MyoCycle FES Cycling Therapy System for home use, aiming to improve rehabilitation for individuals with physical limitations or disabilities [1][2][3] Company Overview - Lifeward is a global leader in innovative medical technology focused on transforming the lives of individuals with physical limitations or disabilities, with a portfolio that includes products like the ReWalk Exoskeleton and the MyoCycle FES System [4] - MYOLYN specializes in functional electrical stimulation therapy, with its flagship product, the MyoCycle, designed to provide therapeutic exercise for individuals with muscle weakness or paralysis [6] Partnership Expansion - The new contract allows Lifeward to manage referrals and sales of the MyoCycle Home product for patients transitioning from clinical to home use, building on an existing distribution agreement for hospital and clinic-based sales [2][3] - MYOLYN will continue to service patients already discharged from therapy, focusing on maximizing their health and recovery through home FES cycling programs [2] Strategic Goals - The partnership aims to better serve patients who have completed therapy in clinics and wish to continue rehabilitation at home, leveraging Lifeward's case management infrastructure to support anticipated growth in the MyoCycle product line [3]

Core Insights - Lifeward Ltd. will release its fourth quarter and fiscal year-end financial results on March 7, 2025, before market opening [1] - The conference call to discuss the financial results will be hosted by CEO Larry Jasinski and CFO Mike Lawless at 8:30 a.m. EST [2] - Lifeward is a leader in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities [3] Company Overview - Lifeward designs, develops, and commercializes solutions for physical rehabilitation and recovery, providing health benefits in clinical and home settings [3] - The company's mission focuses on driving innovation to empower individuals with physical limitations [3] - Lifeward's product portfolio includes the ReWalk Exoskeleton, AlterG Anti-Gravity system, ReStore Exo-Suit, and MyoCycle FES System [3] Company Background - Founded in 2001, Lifeward operates in the United States, Israel, and Germany [4] - The company is committed to delivering groundbreaking solutions for rehabilitation and recovery [3][4]

Core Points - Lifeward Ltd. announces the retirement of CEO Larry Jasinski after 13 years, with a transition period extending through Q2 2025 [1][4] - The company has initiated a search for a new CEO, considering both internal and external candidates [2] - Lifeward expects to report approximately $25.7 million in revenue for the year ended December 31, 2024, within its guidance range of $25 million to $26 million [3] - The company anticipates annual GAAP operating expenses of about $33.4 million, including $5.7 million in restructuring and impairment expenses [3] - A virtual investor event originally scheduled for February 20, 2025, will be rescheduled to later in 2025 following the appointment of the new CEO [3] Company Overview - Lifeward is a global leader in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities [1][5] - The company’s product portfolio includes the ReWalk Exoskeleton, AlterG Anti-Gravity System, MyoCycle FES System, and ReStore Exo-Suit, which are designed to provide functional and health benefits in rehabilitation [5] - Founded in 2001, Lifeward operates in the United States, Israel, and Germany, focusing on delivering groundbreaking solutions for physical rehabilitation [5]

Core Insights - Lifeward has signed a contractual agreement with BARMER, Germany's second largest statutory health insurance company, to streamline access to ReWalk Personal Exoskeletons for eligible beneficiaries [1][2] - Approximately 45% of individuals with Statutory Health Insurance in Germany now have coverage policies that include a defined reimbursement process for personal exoskeletons [1] - BARMER has over 8.5 million insured beneficiaries and has already provided 20 ReWalk Personal Exoskeletons, establishing itself as the leading insurer in Germany for this technology [2] Company Overview - Lifeward is a global leader in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities [1][4] - The company designs, develops, and commercializes solutions that span the continuum of care in physical rehabilitation and recovery [4] - Lifeward's product portfolio includes the ReWalk Exoskeleton, AlterG Anti-Gravity System, MyoCycle FES System, and ReStore Exo-Suit [4] Industry Context - The agreement with BARMER is expected to set a precedent for further expansion of insurance coverage for exoskeletons in Germany and globally [2] - There has been an acceleration in reimbursement policies for exoskeletons, with notable developments in the U.S. and Hungary [2] - The contractual agreement aims to establish sustainable structures in the supply of exoskeletons, ensuring high-quality standards for policyholders [3]

Core Viewpoint - Lifeward Ltd. is hosting a virtual Investor Event on February 20, 2025, to discuss its strategy, key initiatives, and financial outlook, showcasing its innovative medical technology products [1][3]. Company Overview - Lifeward is a global leader in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities [1][4]. - The company designs, develops, and commercializes solutions that span the continuum of care in physical rehabilitation and recovery, delivering functional and health benefits in clinical settings and at home [4]. Product Highlights - The event will feature key products from Lifeward's portfolio, including: - The ReWalk Exoskeleton, which addresses unmet medical needs for individuals with spinal cord injuries [2]. - The AlterG Anti-Gravity System, recognized as the standard of care for rehabilitation of various orthopedic and neurological conditions [2][4]. - Other innovative products include the MyoCycle FES System and the ReStore Exo-Suit [4]. Event Details - The Investor Event will be accessible via a live webcast for investors, analysts, media, and other interested parties, with a replay available on Lifeward's Investor Relations website [3].

Company Overview - Lifeward designs, develops, and commercializes life-changing solutions for physical rehabilitation and recovery, including products like the ReWalk Exoskeleton, AlterG Anti-Gravity System, MyoCycle FES System, and ReStore Exo-Suit [6] - The company was founded in 2001 and operates in the United States, Israel, and Germany [7] - Lifeward's mission is to drive innovation to change the lives of individuals with physical limitations or disabilities [2] 2024 Achievements - Achieved a defined Exoskeleton category as an orthotic brace classified for lump sum payment with CMS, a significant industry milestone [3] - Delivered over 70 new ReWalk systems in 2024, more than double the prior year's total [5] - Established a pipeline of approximately 100 qualified users for future ReWalk submissions [5] - Successfully launched the NEO and NEO+ additions to the AlterG product line, expanding market penetration [5] - Completed operational consolidation of AlterG, including the closure of the Fremont facility, expected to reduce overhead and operating costs [5] - Recovered from initial headwinds in the U.S. capital equipment market, with over 140 AlterG units placed in Q4 2024, up 90% sequentially [5] 2025 Objectives - Focus on driving Exoskeleton adoption through digital marketing, building relationships with key centers, streamlining patient experience, and expanding physician education [5] - Expand AlterG penetration to national chains and international distributors with the new NEO and NEO+ offerings [5] - Complete FDA and CE clearance for ReWalk 7 in the first half of 2025, featuring cloud connectivity, multiple walking speeds, crutch-based control, and improved batteries [5] - Aim to achieve non-GAAP operating profitability by the second half of 2026 [4] - Hold an investor event in New York City on February 20, 2025, to provide more in-depth information and interaction [6] Financial Highlights - Preliminary 2024 financial results met revised revenue guidance [4] - Successfully raised $5 million in additional capital in early 2025 to support Exoskeleton and AlterG awareness, adoption, and liquidity [4] - Financial priorities include driving efficient, sustainable growth, increasing margins, and reducing expenses [5]

Company Announcement - Lifeward Ltd has cancelled its previously announced Extraordinary General Meeting of Shareholders scheduled for January 13, 2025 [1] - The Board of Directors has withdrawn the proposals set forth in the Definitive Proxy Statement filed on November 25, 2024 [1] - The Board intends to present these proposals at a subsequent meeting in 2025 [1] Company Overview - Lifeward designs, develops, and commercializes life-changing solutions in physical rehabilitation and recovery [2] - The company's mission is to drive innovation to change the lives of individuals with physical limitations or disabilities [2] - Lifeward's product portfolio includes the ReWalk Exoskeleton, AlterG Anti-Gravity System, MyoCycle FES System, and ReStore Exo-Suit [2] Company Operations - Lifeward was founded in 2001 and has operations in the United States, Israel, and Germany [3] - Lifeward, ReWalk, ReStore, and AlterG are registered trademarks of Lifeward Ltd and/or its affiliates [3]

Company Overview - Lifeward Ltd is a global market leader in delivering life-changing solutions for rehabilitation, recovery, and enabling individuals with physical limitations or disabilities to pursue their passions [1] - The company designs, develops, and commercializes innovative products across the continuum of care in physical rehabilitation and recovery, including the ReWalk Exoskeleton, AlterG Anti-Gravity System, MyoCycle FES System, and ReStore Exo-Suit [6] - Founded in 2001, Lifeward has operations in the United States, Israel, and Germany [7] Capital Raising Activities - Lifeward closed a registered direct offering of 1,818,183 ordinary shares at $2.75 per share, raising approximately $5.0 million in gross proceeds [1][2] - In a concurrent private placement, the company issued unregistered short-term warrants to purchase up to 1,818,183 ordinary shares, with a three-year term, immediate exercisability, and an exercise price of $2.75 per share [1] - H C Wainwright & Co acted as the exclusive placement agent for the offering [2] - The net proceeds will be used for continuing commercial efforts, working capital, and general corporate purposes [2] Regulatory and Legal Information - The ordinary shares were offered pursuant to a shelf registration statement on Form S-3 (Registration No 333-263984) previously filed with and declared effective by the SEC [3] - The warrants and underlying ordinary shares were issued in a private placement under Section 4(a)(2) of the Securities Act and Regulation D, and are not registered under the Securities Act or applicable state securities laws [4] Business Strategy and Mission - Lifeward's mission is to relentlessly drive innovation to change the lives of individuals with physical limitations or disabilities [6] - The company is committed to delivering groundbreaking solutions that empower individuals to do what they love [6] - Lifeward's products deliver proven functional and health benefits in clinical settings as well as in the home and community [6]

Company Overview - Lifeward Ltd is a global market leader in delivering life-changing solutions for rehabilitation, recovery, and enabling individuals with physical limitations or disabilities to pursue their passions [1] - The company designs, develops, and commercializes innovative products across the continuum of care in physical rehabilitation and recovery, including the ReWalk Exoskeleton, AlterG Anti-Gravity System, MyoCycle FES System, and ReStore Exo-Suit [6] - Founded in 2001, Lifeward has operations in the United States, Israel, and Germany [7] Capital Raising Activities - Lifeward has entered into a definitive agreement for a registered direct offering of 1,818,183 ordinary shares at $2.75 per share, with expected gross proceeds of approximately $5.0 million [1][2] - Concurrently, the company will issue unregistered short-term warrants to purchase up to 1,818,183 ordinary shares, exercisable immediately at $2.75 per share for a term of three years [1] - The offering is expected to close on or about January 8, 2025, subject to customary closing conditions [1] - H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering [2] Use of Proceeds - The net proceeds from the offering will be used for continuing commercial efforts, working capital, and general corporate purposes [2] Regulatory and Legal Information - The ordinary shares are being offered pursuant to a shelf registration statement on Form S-3 (Registration No. 333-263984) previously filed with and declared effective by the SEC [3] - The warrants and underlying ordinary shares are being issued in a private placement under Section 4(a)(2) of the Securities Act and Regulation D, and are not registered under the Securities Act or applicable state securities laws [4] Product Portfolio and Mission - Lifeward's mission is to relentlessly drive innovation to change the lives of individuals with physical limitations or disabilities, empowering them to do what they love [6] - The company's portfolio includes clinically proven and innovative rehabilitation products that deliver functional and health benefits in various settings [6]

Company Overview - Lifeward is a global market leader in delivering life-changing solutions for rehabilitation, recovery, and empowering individuals with physical limitations or disabilities [7] - The company designs, develops, and commercializes innovative products such as the ReWalk Exoskeleton, AlterG Anti-Gravity System, MyoCycle FES System, and ReStore ExoSuit [11] - Founded in 2001, Lifeward has operations in the United States, Israel, and Germany [5] Shareholder Meeting Update - Lifeward has postponed its Extraordinary General Meeting of Shareholders from December 30, 2024, to January 13, 2025, due to an anticipated lack of quorum [7][8] - The record date for the meeting remains November 20, 2024, and shareholders who have already voted do not need to take further action unless they wish to change their vote [8] - The company plans to hold an Investor Day shortly after the postponed meeting, with the exact date to be confirmed [9] Proxy Statement and Shareholder Information - Lifeward filed a Definitive Proxy Statement with the SEC on November 25, 2024, which shareholders are urged to read carefully as it contains important information about the meeting [10] - Shareholders can access the proxy statement and other relevant documents on the SEC's website or the "SEC Filings" section of Lifeward's website [10]